688177 百奥泰
已收盘 11-05 15:00:00
资讯
新帖
简况
业绩承压、为何仍花5000万元收回6年前授权出去的产品？百奥泰回应每经采访
每日经济新闻 · 11-05 21:13
业绩承压、为何仍花5000万元收回6年前授权出去的产品？百奥泰回应每经采访
百奥泰最新公告：戈利木单抗注射液获药品注册证书
证券之星 · 11-05 17:48
百奥泰最新公告：戈利木单抗注射液获药品注册证书
新华健康｜百奥泰收回贝伐珠单抗中国权益 同品类赛道拥挤
经济参考网 · 11-04 22:43
新华健康｜百奥泰收回贝伐珠单抗中国权益 同品类赛道拥挤
股市必读：百奥泰新发布《百奥泰 关于召开2026年第三季度业绩说明会的公告》
证券之星 · 11-04 04:40
股市必读：百奥泰新发布《百奥泰 关于召开2026年第三季度业绩说明会的公告》
百奥泰贝伐珠单抗生物类似药遭百济神州“退货”；华海药业HB0056注射液慢阻肺病适应证获批临床丨医药早参
每日经济新闻 · 11-03 07:01
百奥泰贝伐珠单抗生物类似药遭百济神州“退货”；华海药业HB0056注射液慢阻肺病适应证获批临床丨医药早参
百奥泰（688177）披露BAT1706（贝伐珠单抗）业务发展最新情况，11月02日股价上涨2.81%
证券之星 · 11-02
百奥泰（688177）披露BAT1706（贝伐珠单抗）业务发展最新情况，11月02日股价上涨2.81%
百奥泰：永和工厂复检相关工作在努力推进中
证券之星 · 10-29
百奥泰：永和工厂复检相关工作在努力推进中
百奥泰(688177)9月30日股东户数1.18万户，较上期增加20.44%
证券之星 · 10-28
百奥泰(688177)9月30日股东户数1.18万户，较上期增加20.44%
股市必读：百奥泰新发布《百奥泰 关于优卓美?（司库奇尤单抗注射液）获得药品注册证书的公告》
证券之星 · 10-26
股市必读：百奥泰新发布《百奥泰 关于优卓美?（司库奇尤单抗注射液）获得药品注册证书的公告》
百奥泰（688177）10月23日主力资金净买入41.06万元
证券之星 · 10-24
百奥泰（688177）10月23日主力资金净买入41.06万元
和铂医药与石药集团合作推进的巴托利单抗获批上市；百奥泰司库奇尤单抗注射液获药品注册证书｜医药早参
每日经济新闻 · 10-23
和铂医药与石药集团合作推进的巴托利单抗获批上市；百奥泰司库奇尤单抗注射液获药品注册证书｜医药早参
百奥泰(688177.SH)：优卓美®(司库奇尤单抗注射液)获得药品注册证书
智通财经 · 10-22
百奥泰(688177.SH)：优卓美®(司库奇尤单抗注射液)获得药品注册证书
百奥泰（688177）10月20日主力资金净买入124.72万元
证券之星 · 10-21
百奥泰（688177）10月20日主力资金净买入124.72万元
百奥泰（688177）10月8日主力资金净卖出91.37万元
证券之星 · 10-09
百奥泰（688177）10月8日主力资金净卖出91.37万元
百奥泰（688177）9月29日主力资金净卖出550.49万元
证券之星 · 09-30
百奥泰（688177）9月29日主力资金净卖出550.49万元
每周股票复盘：百奥泰（688177）将召开两场业绩说明会
证券之星 · 09-13
每周股票复盘：百奥泰（688177）将召开两场业绩说明会
百奥泰获得发明专利授权：“多特异性抗体及其应用”
证券之星 · 09-11
百奥泰获得发明专利授权：“多特异性抗体及其应用”
每周股票复盘：百奥泰（688177）财务总监辞职董事长代行职责
证券之星 · 09-06
每周股票复盘：百奥泰（688177）财务总监辞职董事长代行职责
股市必读：百奥泰新发布《百奥泰 关于公司财务总监辞职暨董事长、总经理代行财务总监职责的公告》
证券之星 · 09-03
股市必读：百奥泰新发布《百奥泰 关于公司财务总监辞职暨董事长、总经理代行财务总监职责的公告》
百奥泰（688177）披露财务总监辞职暨董事长代行相关职责公告，9月1日股价下跌2.2%
证券之星 · 09-01
百奥泰（688177）披露财务总监辞职暨董事长代行相关职责公告，9月1日股价下跌2.2%
暂无数据
公司概况
公司名称：
百奥泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-02-21
主营业务：
百奥泰生物制药股份有限公司的主营业务是开发创新药和生物类似药。公司的主要产品是格乐立、普贝希、施瑞立、贝塔宁、艾沙力、Gotenfia。
发行价格：
32.76
{"stockData":{"symbol":"688177","market":"SH","secType":"STK","nameCN":"百奥泰","latestPrice":17.82,"timestamp":1793862000000,"preClose":17.31,"halted":0,"volume":3096081,"delay":0,"changeRate":0.0295,"floatShares":413999999,"shares":413999999,"eps":-1.0651,"marketStatus":"已收盘","change":0.51,"latestTime":"11-05 15:00:00","open":17.31,"high":17.99,"low":17.31,"amount":54836800,"amplitude":0.0393,"askPrice":17.83,"askSize":13,"bidPrice":17.82,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-1.0651,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793928600000},"marketStatusCode":5,"adr":0,"adjPreClose":17.31,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793842200000,1793849400000],[1793854800000,1793862000000]],"highLimit":19.04,"lowLimit":15.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":414080000,"isCdr":false,"pbRate":171.85,"roa":"--","roe":"--","epsLYR":-0.8,"committee":0.298507,"marketValue":7379000000,"turnoverRate":0.0075,"status":0,"afterMarket":{"amount":0,"volume":0,"close":17.82,"buyVolume":0,"sellVolume":0,"time":1793864037746,"indexStatus":"已收盘 11-05 15:30:00","preClose":17.31},"floatMarketCap":7379000000},"requestUrl":"/m/hq/s/688177/tweets","defaultTab":"tweets","newsList":[{"id":"2681128075","title":"业绩承压、为何仍花5000万元收回6年前授权出去的产品？百奥泰回应每经采访","url":"https://stock-news.laohu8.com/highlight/detail?id=2681128075","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681128075?lang=zh_cn&edition=full","pubTime":"2026-11-05 21:13","pubTimestamp":1793884431,"startTime":"0","endTime":"0","summary":"“在集采常态化背景下，产品需要更灵活的市场化策略来适配规则。自主掌控普贝希的运营节奏之后，公司可以更高效统筹生产、定价及落地安排。”百奥泰（SH688177，股价17.82元，市值73.79亿元）在接受《每日经济新闻》记者（以下简称每经记者）采访时如是回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611053923767648.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611053923767648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681304038","title":"百奥泰最新公告：戈利木单抗注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2681304038","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681304038?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:48","pubTimestamp":1793872102,"startTime":"0","endTime":"0","summary":"百奥泰(688177.SH)公告称，公司近日收到国家药监局核准签发的戈利木单抗注射液(商品名：阿舒立)《药品注册证书》，该药品为治疗用生物制品3.3类，用于类风湿关节炎、强直性脊柱炎。阿舒立为国内首款戈利木单抗生物类似药，其获批上市有助于提升公司产品市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500031265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680050739","title":"新华健康｜百奥泰收回贝伐珠单抗中国权益 同品类赛道拥挤","url":"https://stock-news.laohu8.com/highlight/detail?id=2680050739","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680050739?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:43","pubTimestamp":1793803427,"startTime":"0","endTime":"0","summary":"签约六年后，百奥泰（688177.SH）与百济神州（688235.SH，纳斯达克代码：ONC；香港联交所代码：06160）围绕贝伐珠单抗生物类似药BAT1706（国内商品名普贝希?）的合作画上句号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611043922307842.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611043922307842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680742137","title":"股市必读：百奥泰新发布《百奥泰 关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680742137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680742137?lang=zh_cn&edition=full","pubTime":"2026-11-04 04:40","pubTimestamp":1793738424,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘，百奥泰报收于16.57元，下跌1.49%，换手率0.82%，成交量3.4万手，成交额5641.09万元。公司公告汇总百奥泰 关于召开2026年第三季度业绩说明会的公告百奥泰生物制药股份有限公司将于2026年11月11日15:00-16:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司2026年第三季度经营成果及财务状况。百奥泰2026年第三次临时股东会会议资料百奥泰生物制药股份有限公司召开2026年第三次临时股东会，审议两项关联交易议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400006535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680791112","title":"百奥泰贝伐珠单抗生物类似药遭百济神州“退货”；华海药业HB0056注射液慢阻肺病适应证获批临床丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2680791112","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680791112?lang=zh_cn&edition=full","pubTime":"2026-11-03 07:01","pubTimestamp":1793660501,"startTime":"0","endTime":"0","summary":"丨2026年11月3日星期二丨NO.1百奥泰贝伐珠单抗生物类似药遭百济神州“退货”11月2日，百奥泰公告称，基于对公司和百济神州双方均有利的战略考量，经双方协商一致，公司于2026年11月1日从百济神州重新获得BAT1706（贝伐珠单抗）相关知识产权及其在中国地区的全部产品权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033919222498.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033919222498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU2272731782.SGD","ONC","LU1770034418.SGD","LU2272731865.HKD","BK0185","BK1574","LU0588546209.SGD","LU2328871848.SGD","BK1500","BK0201","BK0012","XPH","BK4526","LU1719994722.HKD","LU2473716301.USD","BK1515","LU0228659784.USD","159938","BK1161","KURE","BK0070","BK1583","09939","LU2272731600.USD","BK0239","IE00B5TLWC47.USD","BK0188","BK4585","LU0828237510.HKD","LU2322448791.USD","PPH","LU1992135472.HKD","LU2322448957.HKD","LU1251922891.USD","LU1969619763.USD","688235","BK0028","LU0307460666.USD","BK1588","LU1303224171.USD","BK4139","600521","IBB","06160","LU1992135399.USD","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680765465","title":"百奥泰（688177）披露BAT1706（贝伐珠单抗）业务发展最新情况，11月02日股价上涨2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680765465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680765465?lang=zh_cn&edition=full","pubTime":"2026-11-02 22:39","pubTimestamp":1793630399,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘，百奥泰报收于16.82元，较前一交易日上涨2.81%，最新总市值为69.65亿元。该股当日开盘16.37元，最高17.0元，最低16.07元，成交额达5735.58万元，换手率为0.84%。近日，百奥泰生物制药股份有限公司发布《关于BAT1706业务发展最新情况的公告》。公告显示，2026年11月1日，公司与百济神州有限公司经协商一致，重新获得BAT1706相关知识产权及在中国地区的全部产品权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200037334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679947963","title":"百奥泰：永和工厂复检相关工作在努力推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2679947963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679947963?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:30","pubTimestamp":1793266233,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰(688177)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好。欧洲复检有什么新进展吗？百奥泰回复：尊敬的投资者您好！永和工厂复检相关工作在努力推进中，公司将严格按照法律和相关规定及时履行信息披露义务。感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900042225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678463242","title":"百奥泰(688177)9月30日股东户数1.18万户，较上期增加20.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678463242","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678463242?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:33","pubTimestamp":1793183627,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百奥泰披露，截至2026年9月30日公司股东户数为1.18万户，较6月30日增加1997.0户，增幅为20.44%。在生物制品行业个股中，百奥泰股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.58万户。从股价来看，2026年6月30日至2026年9月30日，百奥泰区间涨幅为25.03%，在此期间股东户数增加1997.0户，增幅为20.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800040214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678132334","title":"股市必读：百奥泰新发布《百奥泰 关于优卓美?（司库奇尤单抗注射液）获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678132334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678132334?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:02","pubTimestamp":1792972978,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，百奥泰报收于18.11元，上涨4.44%，换手率0.92%，成交量3.82万手，成交额6649.83万元。优卓美为全球首个司库奇尤单抗生物类似药，已获得多个国家和地区商业化授权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600002197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677903150","title":"百奥泰（688177）10月23日主力资金净买入41.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677903150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677903150?lang=zh_cn&edition=full","pubTime":"2026-10-24 08:21","pubTimestamp":1792801285,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月23日收盘，百奥泰报收于18.11元，上涨4.44%，换手率0.92%，成交量3.82万手，成交额6649.83万元。近5日资金流向一览见下表：百奥泰融资融券信息显示，融资方面，当日融资买入349.79万元，融资偿还417.89万元，融资净偿还68.1万元。百奥泰主营业务：药物的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400006921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677970579","title":"和铂医药与石药集团合作推进的巴托利单抗获批上市；百奥泰司库奇尤单抗注射液获药品注册证书｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2677970579","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677970579?lang=zh_cn&edition=full","pubTime":"2026-10-23 07:01","pubTimestamp":1792710089,"startTime":"0","endTime":"0","summary":"｜2026年10月23日星期五｜NO.1和铂医药/石药集团1类新药巴托利单抗获批上市，治疗全身型重症肌无力10月22日，NMPA官网显示，和铂医药与石药集团合作推进的1类新药巴托利单抗在国内获批上市，用于治疗全身型重症肌无力（gMG）。巴托利单抗是一种全人源单克隆抗体，靶向新生儿Fc受体（FcRn）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233904682844.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233904682844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1813983027.USD","BK1191","IE00BZ08YT58.USD","LU1226287875.USD","IE00BZ08YS42.EUR","LU0067412154.USD","01093","LU1328277881.USD","09939","LU1993786604.SGD","IPOS","LU1960683339.HKD","IE0008368742.USD","LU0501845795.SGD","IE00B031HY20.USD","LU0315179316.USD","LU0140636845.USD","LU2039709279.SGD","BK0239","BK1583","IE00BZ08YR35.GBP","SG9999004220.SGD","BK1521","BK1574","LU0314109678.HKD","BK1515","LU1152091168.USD","02142","KURE","LU0072913022.USD","BK1161","LU1226287792.SGD","IE00B543WZ88.USD","HK0000165453.HKD","688177","LU1807302812.USD","IE00B5MMRT66.SGD","LU1951186391.HKD","159938","LU0880133367.SGD","LU0326950275.SGD","LU1226287529.USD","LU1226288170.HKD","LU1152091754.HKD","LU1226288253.USD","LU1008478684.HKD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677958634","title":"百奥泰(688177.SH)：优卓美®(司库奇尤单抗注射液)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2677958634","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677958634?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:44","pubTimestamp":1792658645,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)发布公公，公司于近日收到了国家药品监督管理局(“NMPA”)核准签发的关于司库奇尤单抗注射液(BAT2306，商品名：优卓美®)的《药品注册证书》。适应症：银屑病、强直性脊柱炎、银屑病关节炎。优卓美®为全球首个司库奇尤单抗生物类似药，其获批上市有助于提升公司产品的市场竞争力，对公司经营发展具有积极作用。已上市竞品和其他潜在竞品可能会拥有先行者优势，优卓美®可能在未来面临激烈的市场竞争。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677104446","title":"百奥泰（688177）10月20日主力资金净买入124.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677104446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677104446?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:23","pubTimestamp":1792542232,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月20日收盘，百奥泰报收于17.89元，上涨4.07%，换手率0.84%，成交量3.49万手，成交额6119.58万元。近5日资金流向一览见下表：百奥泰融资融券信息显示，融资方面，当日融资买入456.88万元，融资偿还255.74万元，融资净买入201.15万元。百奥泰主营业务：药物的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674310889","title":"百奥泰（688177）10月8日主力资金净卖出91.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674310889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674310889?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:26","pubTimestamp":1791505614,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，百奥泰报收于19.23元，下跌8.56%，换手率1.32%，成交量5.49万手，成交额1.08亿元。近5日资金流向一览见下表：百奥泰融资融券信息显示，融资方面，当日融资买入734.97万元，融资偿还406.89万元，融资净买入328.08万元。百奥泰主营业务：药物的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671225752","title":"百奥泰（688177）9月29日主力资金净卖出550.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671225752","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671225752?lang=zh_cn&edition=full","pubTime":"2026-09-30 08:30","pubTimestamp":1790728237,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月29日收盘，百奥泰报收于20.21元，下跌2.13%，换手率1.08%，成交量4.49万手，成交额9122.23万元。9月29日的资金流向数据方面，主力资金净流出550.49万元，占总成交额6.03%，游资资金净流出564.02万元，占总成交额6.18%，散户资金净流入1114.51万元，占总成交额12.22%。近5日资金流向一览见下表：百奥泰融资融券信息显示，融资方面，当日融资买入459.19万元，融资偿还496.08万元，融资净偿还36.9万元。百奥泰主营业务：药物的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000006721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667003325","title":"每周股票复盘：百奥泰（688177）将召开两场业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667003325","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667003325?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:03","pubTimestamp":1789239792,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，百奥泰报收于16.24元，较上周的17.48元下跌7.09%。本周，百奥泰9月7日盘中最高价报17.62元。百奥泰生物制药股份有限公司将参加由中国证券监督管理委员会广东监管局及广东上市公司协会主办的“2026年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明会活动”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513401","title":"百奥泰获得发明专利授权：“多特异性抗体及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666513401?lang=zh_cn&edition=full","pubTime":"2026-09-11 03:46","pubTimestamp":1789069597,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示百奥泰新获得一项发明专利授权，专利名为“多特异性抗体及其应用”，专利申请号为CN202180037470.3，授权日为2026年9月4日。今年以来百奥泰新获得专利授权5个，较去年同期增加了150%。通过天眼查大数据分析，百奥泰生物制药股份有限公司共对外投资了3家企业，参与招投标项目131次；财产线索方面有商标信息161条，专利信息175条，著作权信息4条；此外企业还拥有行政许可464个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100009566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665668113","title":"每周股票复盘：百奥泰（688177）财务总监辞职董事长代行职责","url":"https://stock-news.laohu8.com/highlight/detail?id=2665668113","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665668113?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:02","pubTimestamp":1788634937,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，百奥泰报收于17.48元，较上周的18.63元下跌6.17%。本周，百奥泰8月31日盘中最高价报18.63元。百奥泰当前最新总市值72.38亿元，在生物制品板块市值排名34/51，在两市A股市值排名2382/5214。公司公告汇总百奥泰生物制药股份有限公司董事会于近日收到财务总监占先红女士的书面辞职报告，其因个人原因辞去财务总监职务，辞职后不再担任公司任何职务。该辞职报告自送达董事会之日起生效。公司及董事会对其任职期间的贡献表示感谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846379","title":"股市必读：百奥泰新发布《百奥泰 关于公司财务总监辞职暨董事长、总经理代行财务总监职责的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846379","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664846379?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:52","pubTimestamp":1788375131,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，百奥泰报收于17.65元，下跌0.9%，换手率0.72%，成交量2.98万手，成交额5246.17万元。当日关注点交易信息汇总：9月2日主力资金净流出89.52万元，占总成交额1.71%。公司公告汇总：财务总监占先红因个人原因辞职，董事长、总经理李胜峰代行财务总监职责，自9月1日董事会决议生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300002349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664830833","title":"百奥泰（688177）披露财务总监辞职暨董事长代行相关职责公告，9月1日股价下跌2.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664830833","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664830833?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:37","pubTimestamp":1788255428,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，百奥泰报收于17.81元，较前一交易日下跌2.2%，最新总市值为73.75亿元。该股当日开盘18.17元，最高18.3元，最低17.69元，成交额达8272.19万元，换手率为1.11%。公告显示，公司董事会于近日收到财务总监占先红女士的书面辞职报告，其因个人原因辞去财务总监职务，辞职后不再担任公司任何职务。该辞职报告自送达董事会之日起生效。公司及董事会对其任职期间的贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100030995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793915495053,"stockEarnings":[{"period":"1week","weight":0.0526},{"period":"1month","weight":-0.1526},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.1108},{"period":"1year","weight":-0.325},{"period":"ytd","weight":-0.2299}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.0704},{"period":"ytd","weight":-0.0703}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11765人(较上一季度增加20.44%)","perCapita":"35195股","listingDate":"2020-02-21","address":"广东省广州市黄埔区国际生物岛螺旋二路18号","registeredCapital":"41408万元","survey":" 百奥泰生物制药股份有限公司的主营业务是开发创新药和生物类似药。公司的主要产品是格乐立、普贝希、施瑞立、贝塔宁、艾沙力、Gotenfia。","listedPrice":32.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥泰,688177,百奥泰股票,百奥泰股票老虎,百奥泰股票老虎国际,百奥泰行情,百奥泰股票行情,百奥泰股价,百奥泰股市,百奥泰股票价格,百奥泰股票交易,百奥泰股票购买,百奥泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}